STEM-PD is a clinical trial run by clinical and preclinical research teams in Sweden and the UK. The goal of the trial is to develop a safe and efficacious stem cell-based treatment for Parkinson’s disease.

The trial involves transplantation of stem cell-derived dopamine STEM-PD cells into the brains of Parkinson’s disease patients. The stem cell product to be transplanted in this trial is named “STEM-PD”. The cells are designed to form new functional dopamine neurons in the brain of the patient after transplantation, with the aim of replacing those neurons which have been lost during the course of the disease.

This clinical trial is an investigator-lead clinical trial sponsored by Skåne University Hospital in Lund and registered as EudraCT 2021-001366-38. The development of the product and the clinical trial has been funded by national and EU funding agencies as well as by the pharmaceutical company Novo Nordisk.